Target intelligence / Profile preview

Lipopolysaccharide lipid A (Lipid A) (Lipid A)

Target
Lipid A
Molecular classification
Glycolipid, Bacterial endotoxin, Cell wall component
01

Overview

Lipopolysaccharide lipid A is the highly conserved, hydrophobic anchor of the lipopolysaccharide (LPS) molecule, embedded within the outer leaflet of the Gram-negative bacterial outer membrane (Raetz & Whitfield, 2002). It is widely recognized as the 'endotoxin' component of the bacterial cell wall, responsible for the potent inflammatory response triggered during Gram-negative infections (Park et al., 2009). Lipid A is essential for bacterial viability and serves as a critical permeability barrier, protecting the cell from toxic substances. This essentiality makes it a primary target for cationic antimicrobial peptides such as polymyxin B and colistin, which bind to the lipid A phosphate groups to disrupt membrane integrity (Velkov et al., 2013). In the host, lipid A is detected by the Toll-like receptor 4 (TLR4)/MD-2 complex, which initiates a signaling cascade leading to the production of pro-inflammatory cytokines (Opal, 2010). While this immune activation is vital for controlling infection, excessive or systemic release of lipid A can lead to life-threatening conditions such as sepsis and septic shock (Opal et al., 2013). Consequently, lipid A is a major focus for both the development of novel antibiotics and the creation of anti-sepsis therapies designed to neutralize its toxic effects.

Other names
EndotoxinLipid A moietyLPS lipid ALipid A componentLipoglycan lipid A
02

Mechanism of action

Polymyxin antibiotics bind to the lipid A moiety of lipopolysaccharide, displacing stabilizing divalent cations and causing disruption of the bacterial outer membrane, which leads to increased permeability and cell death (Velkov et al., 2013).

03

Biological functions

Structural integrity of the outer membraneInnate immune system activationEndotoxic activityPermeability barrier
04

Disease associations

SepsisSeptic shockGram-negative bacterial infectionInflammation
05

Safety considerations

NephrotoxicityNeurotoxicityJarisch-Herxheimer-like reactionsAntibiotic resistance via lipid A modification (e.g., mcr-1)
06

Interacting drugs

Polymyxin B

2 more in the full profile.

07

Biomarkers

Serum lipopolysaccharide levelsLipopolysaccharide-binding protein (LBP)ProcalcitoninEndotoxin Activity Assay (EAA)

Beyond the preview

Go deeper on Lipopolysaccharide lipid A (Lipid A) (Lipid A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lipopolysaccharide lipid A (Lipid A) (Lipid A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call